When Teva Pharmaceutical Industries Ltd.'s /zigman2/quotes/205657894/composite TEVA +0.36% generic version of the EpiPen allergic reaction treatment was approved last week, amid spot shortages of the branded product and concerns about allergic children needing the products as they go back to school, the timing seemed perfect. But Teva may not be launching the product soon enough, according to SunTrust Robinson Humphrey analyst John Boris, who noted that wholesalers are not expecting the products from Teva for a couple of months, "potentially missing the back-to-school season." Reached for comment, a Teva spokesperson would not comment specifically on the analyst report, referring MarketWatch to a statement made last week that the company "is applying its full resources to this important launch in the coming months and is eager to begin supplying the market." Teva has also not yet published the list prices of the products, the spokesperson said. Individuals across the country have reported difficulties purchasing the EpiPen in recent months, including one parent who told MarketWatch she called between eight and 10 pharmacies before she was able to buy a package for her allergic six-year-old. While Labor Day is traditionally thought of as back-to-school season, schools in some parts of the country start as early as July, and elsewhere August is considered the new September, CNN has previously reported . In addition to approving the Teva generic, the Food and Drug Administration worked with Pfizer, which manufactures Mylan's EpiPen , to extend expiration dates on certain EpiPen lots by about four months; Pfizer also said it now expects supply to stabilize in the fourth-quarter. Teva shares declined 1.3% in Friday morning trade. Shares have risen 8.5% over the last three months, compared with a 5.1% rise in the S&P 500 /zigman2/quotes/210599714/realtime SPX -0.58% and a 3.7% rise in the Dow Jones Industrial Average /zigman2/quotes/210598065/realtime DJIA -0.75% .